Abstract
Type 1 diabetes (T1D) is an organ-specific autoimmune disease resulting from the specific destruction of insulin-producing pancreatic β-cells, culminating in a state of hypoinsulinemia and hyperglycemia. Pathogenesis of T1D comprises complex series of events from the initial sensitization of antigen-presenting cells (APCs) to β-cell antigens to almost total insulin deficiency due to islet destruction. Although it is established that the interaction of environmental factors with genetic traits plays a pivotal role in the pathogenesis of T1D, in most cases, the exact trigger of anti-islet autoimmunity and how genetic and environmental factors regulate its progression, ultimately leading to the development of T1D remain elusive. In this review, based on the recent advances in understanding the role of innate immunity in development of autoimmune diseases, we focus on the possibility that aberrant regulation of the innate immune system frequently observed in animal models and patients with T1D, induces T1D by triggering anti-islet autoimmunity in the context of the autoimmuneprone environment; this information might provide an insight into possibilities for therapeutic intervention modulating innate immunity to mitigate or prevent T1D.
Keywords: Innate immunity, β-cell death, macrophages, dendritic cells, NK cells, NK T cells, γδ T cells, TLRs
Current Molecular Medicine
Title: Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes
Volume: 9 Issue: 1
Author(s): Hun Sik Kim and Myung-Shik Lee
Affiliation:
Keywords: Innate immunity, β-cell death, macrophages, dendritic cells, NK cells, NK T cells, γδ T cells, TLRs
Abstract: Type 1 diabetes (T1D) is an organ-specific autoimmune disease resulting from the specific destruction of insulin-producing pancreatic β-cells, culminating in a state of hypoinsulinemia and hyperglycemia. Pathogenesis of T1D comprises complex series of events from the initial sensitization of antigen-presenting cells (APCs) to β-cell antigens to almost total insulin deficiency due to islet destruction. Although it is established that the interaction of environmental factors with genetic traits plays a pivotal role in the pathogenesis of T1D, in most cases, the exact trigger of anti-islet autoimmunity and how genetic and environmental factors regulate its progression, ultimately leading to the development of T1D remain elusive. In this review, based on the recent advances in understanding the role of innate immunity in development of autoimmune diseases, we focus on the possibility that aberrant regulation of the innate immune system frequently observed in animal models and patients with T1D, induces T1D by triggering anti-islet autoimmunity in the context of the autoimmuneprone environment; this information might provide an insight into possibilities for therapeutic intervention modulating innate immunity to mitigate or prevent T1D.
Export Options
About this article
Cite this article as:
Kim Sik Hun and Lee Myung-Shik, Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes, Current Molecular Medicine 2009; 9 (1) . https://dx.doi.org/10.2174/156652409787314471
DOI https://dx.doi.org/10.2174/156652409787314471 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus
Current Gene Therapy Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies
Current Rheumatology Reviews Interferon: Cellular Executioner or White Knight?
Current Medicinal Chemistry Cholecystokinin-8 and Nerve Growth Factor: two Endogenous Molecules Working for the Upkeep and Repair of the Nervous System
Current Drug Targets - CNS & Neurological Disorders Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets The TGF-β 1/Foxp3 Regulatory Axis in Immune Self-Tolerance: Implications for Health and Disease
Inflammation & Allergy - Drug Targets (Discontinued) mTOR Signaling and Metabolic Regulation of T Cells: New Potential Therapeutic Targets in Autoimmune Diseases
Current Pharmaceutical Design The Relationship Between Social Support, Social Constraint, and Psychological Adjustment for Patients with Rare Autoimmune Disease
Current Rheumatology Reviews Vitiligo and Allergic Complications from Orthopaedic Joint Implants: The Role of Benzoyl Peroxide
Recent Patents on Inflammation & Allergy Drug Discovery Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod
Current Drug Targets Vitiligo in Children: A Birds Eye View
Current Pediatric Reviews A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry Targeting T-Cell Adhesion Molecules for Drug Design
Current Pharmaceutical Design The Unique Inhibitory IgG Receptor--FcγRIIb
Protein & Peptide Letters Glucocorticoids Pharmacology: Past, Present and Future
Current Pharmaceutical Design The Effects of Dehydroepiandrosterone (DHEA) in the Treatment of Depression and Depressive Symptoms in Other Psychiatric and Medical Illnesses: A Systematic Review
Current Drug Targets B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued)